Replies to post #244343 on Biotech Values

[Biowatch]

But dermal fillers are RVNC’s main money-maker…

[DewDiligence]

Botox info from ABBV's 3Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/10/28/abbvie-abbv-q3-2022-earnings-call-transcript/

While our U.S. aesthetics market share remains stable across both toxins and fillers, we now believe it's prudent to adjust our full year aesthetics forecast to reflect the moderating market growth over the near to medium term, which is expected to predominantly impact Juvederm, as well as our body contouring portfolio products, which represent higher price points for consumers.

Emphasis added. I.e. Botox will be affected to a lesser degree than Juvederm dermal fillers and CoolSculpting procedures.